Precision BioSciences (DTIL) Scheduled to Post Earnings on Thursday

Precision BioSciences (NASDAQ:DTIL) is scheduled to release its earnings data before the market opens on Thursday, August 1st. Analysts expect Precision BioSciences to post earnings of ($0.77) per share for the quarter.

Precision BioSciences (NASDAQ:DTIL) last issued its earnings results on Monday, May 13th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.10. Precision BioSciences had a negative net margin of 48.10% and a negative return on equity of 131.69%. The business had revenue of $17.58 million during the quarter, compared to analysts’ expectations of $9.35 million. On average, analysts expect Precision BioSciences to post $-3 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Precision BioSciences Price Performance

Shares of Precision BioSciences stock traded down $0.61 during trading hours on Tuesday, hitting $9.39. The company had a trading volume of 11,728 shares, compared to its average volume of 86,225. The company’s 50-day moving average is $10.84 and its two-hundred day moving average is $11.69. Precision BioSciences has a twelve month low of $8.25 and a twelve month high of $19.43. The company has a market cap of $65.07 million, a P/E ratio of -1.34 and a beta of 1.75.

Analysts Set New Price Targets

Several brokerages have recently issued reports on DTIL. HC Wainwright restated a “buy” rating and issued a $60.00 target price on shares of Precision BioSciences in a report on Thursday, May 30th. Guggenheim assumed coverage on shares of Precision BioSciences in a report on Tuesday, April 30th. They issued a “buy” rating and a $19.00 target price for the company.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.